📰 Epigenetic Regulator Program News
Epigenetic Regulator Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Epigenetic Regulator Program. Real-time updates on events, politics, business and more.
June 15, 2023
DURECT Co. (NASDAQ:DRRX – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 565,100 shares, an increase of 39.9% from the May 15th total of 404,000 shares. Approximately 2.3% of the shares of the stock are short sold. […]
May 20, 2023
Equities researchers at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Rating) in a report released on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock. DRRX has been the subject of several other reports. Jonestrading started coverage on shares of DURECT in a research note on Tuesday, March […]
May 19, 2023
Tocqueville Asset Management L.P. lowered its stake in shares of DURECT Co. (NASDAQ:DRRX – Get Rating) by 89.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 91,240 shares of the specialty pharmaceutical company’s stock after selling 780,160 shares during the period. Tocqueville Asset Management L.P. owned approximately […]
May 17, 2023
DURECT Co. (NASDAQ:DRRX – Get Rating) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 362,400 shares, an increase of 6.6% from the April 15th total of 339,900 shares. Approximately 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of […]
May 17, 2023
DURECT Co. (NASDAQ:DRRX – Get Rating) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 362,400 shares, an increase of 6.6% from the April 15th total of 339,900 shares. Approximately 1.5% of the company’s shares are sold short. Based on […]
April 30, 2023
DURECT Co. (NASDAQ:DRRX – Get Rating) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 339,900 shares, a decrease of 19.9% from the March 31st total of 424,200 shares. Based on an average daily volume of 94,600 shares, the days-to-cover ratio is currently 3.6 days. Approximately […]
April 29, 2023
Susquehanna International Group LLP acquired a new stake in shares of DURECT Co. (NASDAQ:DRRX – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,954 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Susquehanna International […]
April 21, 2023
DURECT Co. (NASDAQ:DRRX – Get Rating) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 424,200 shares, an increase of 13.6% from the March 15th total of 373,300 shares. Based on an average trading volume of 104,600 shares, the short-interest ratio is presently […]
April 5, 2023
Regis Management CO LLC cut its position in DURECT Co. (NASDAQ:DRRX – Get Rating) by 90.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,425 shares of the specialty pharmaceutical company’s stock after selling 120,825 shares during the quarter. Regis Management […]
March 26, 2022
Analysts expect that DURECT Co. (NASDAQ:DRRX – Get Rating) will post sales of $2.43 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for DURECT’s earnings, with estimates ranging from $2.00 million to $2.85 million. DURECT reported sales of $2.21 million during the same quarter last year, which would indicate […]